HeLa-CD19 Cell Line for CAR-T Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack an effective and stable cell line for studying hematopoietic cancer markers and targeting specific tumor antigens, particularly for leukemia and lymphoma, which limits the development of targeted therapies.

Innovation Solution

A transduced Hela cell line (Hela-CD19) that stably expresses the CD19 antigen, allowing for the creation of CAR-T cells and CAR-NK cells to effectively target and kill cancer cells, and can be used in xenograft models to study tumor growth and microenvironment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a cell line is used to study hematopoietic cancer markers, then research on leukemia and lymphoma can be conducted, but the stability and effectiveness of the cell line for targeting specific tumor antigens is insufficient

Engineering Contradiction:

Improvestability of cell lineVSAvoidtargeting capability of tumor antigens

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent merges two previously separate concepts: using solid tumor cell lines (HeLa) and expressing hematopoietic cancer markers (CD19, CD20, CD22) on their surface. This creates a hybrid cell line that combines the stability and ease of culture of solid tumor cells with the relevance to leukemia and lymphoma research, enabling both reliable cell culture and effective targeting by CAR-T cells

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The HeLa-CD19 cell line serves multiple functions: it can be used for in vitro cytotoxicity assays, in vivo xenograft models, and as a target for various CAR-T cell therapies. The cell line is versatile enough to study multiple hematopoietic markers (CD19, CD20, CD22) and can accommodate different experimental conditions while maintaining stability

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Ease of manufacture

If current cell lines are used for studying hematopoietic cancer markers, then some research can be performed, but effective and stable cell lines for targeting specific tumor antigens are lacking

Engineering Contradiction:

Improveease of cell line establishmentVSAvoideffectiveness for therapy development

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent performs preliminary action by pre-establishing the HeLa-CD19 cell line with stable CD19 expression before it is needed for therapy development studies. The cell line is prepared in advance with validated marker expression and characterized for its properties, making it immediately ready for use in CAR-T cell efficacy studies without requiring time-consuming optimization during the research process

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS10086055B2Adherent cancer cell line expressing a hematological tumor antigen

Publication Date: 2018.10.02 VALHALLA VAULT VENTURES LLC

AI summary

The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.